In this model, the contemporary targeting of NKG2D ligands MICA/B on tumor cells, and the inhibitory receptor NKG2A on NK cells, led to a synergistic effect in blocking tumor cell growth, even if it expressed the NKG2A ligand HLA-E [119]. The gene discussed is KLRK1; the disease is neoplasm.